SynthesisBMC urology2026
Meta-analysis of the association between CTCs and survival outcomes in urothelial carcinoma.
Synthesis in BMC urology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
objectiveTo systematically evaluate the correlations between the characteristics of circulating tumor cells (CTCs) and survival outcomes in patients with urothelial carcinoma (UC) receiving first-line chemotherapy.
methodsA comprehensive search was conducted in the PubMed, Embase, Web of Science, and Cochrane Library databases to collect relevant English observational studies (cohort studies or case-control studies) focusing on patients with UC receiving first-line chemotherapy and investigating the associations between CTC characteristics and survival outcomes (progression-free survival [PFS], overall survival [OS]), published from the establishment of the databases to August 2025. Two researchers independently screened the literature based on predefined inclusion and exclusion criteria, extracted the data, and evaluated the quality using the Newcastle-Ottawa Scale (NOS). The main combined indicator was the hazard ratio (HR) and its 95% confidence interval (CI). Statistical analysis was performed using RevMan 5.3 software. The I² statistic was used to assess heterogeneity, and Egger’s test and sensitivity analysis were used to evaluate publication bias and the stability of the results.
resultsA total of 6 studies involving 577 patients with urothelial carcinoma were finally included. The results of the Meta-analysis showed that patients with high-risk CTC characteristics (CTC positivity, high CTC count, or expression of specific molecular markers) had a significantly higher risk of disease progression (HR = 2.84, 95% CI [1.66, 4.83], Z = 3.83, P < 0.001). They also had a significantly higher risk of death (HR = 3.05, 95% CI [1.74, 5.32], Z = 3.91, P < 0.001).
conclusionHigh-risk CTC characteristics are strong predictors of poor survival outcomes in UC. CTC-based liquid biopsy holds promise for risk stratification, especially in metastatic patients, and should be integrated into future prospective trials to validate its utility in guiding individualized therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.